[{"data":1,"prerenderedAt":246},["ShallowReactive",2],{"$f2vkeray51jxm6":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":22,"top_modalities":53,"top_diseases":77,"top_companies":109,"key_results":133,"trends":204,"previous_editions":213,"comparison":217,"highlighted_classes":239},1,"sitc-2026","SITC","sitc","SITC Annual Meeting 2026",2026,"Oncology","2026-11-15T10:10:42Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},1128,647,272,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 2\u002F3":20,"Phase 3":21},76,31,41,2,7,[23,27,30,34,38,41,43,46,48,50],{"name":24,"count":25,"share":26},"PDCD1",83,13,{"name":28,"count":29,"share":21},"CD3",46,{"name":31,"count":32,"share":33},"CD274",38,6,{"name":35,"count":36,"share":37},"CD19",28,4,{"name":39,"count":40,"share":20},"IL2RB",15,{"name":42,"count":40,"share":20},"VEGFA",{"name":44,"count":45,"share":20},"CTLA-4",14,{"name":47,"count":26,"share":20},"B7-H3",{"name":49,"count":26,"share":20},"IL-12R",{"name":51,"count":52,"share":20},"CD28",12,[54,57,61,64,67,69,72,74],{"name":55,"count":56,"share":36},"Monoclonal antibodies",181,{"name":58,"count":59,"share":60},"Small molecules",152,23,{"name":62,"count":63,"share":60},"Cell therapies",146,{"name":65,"count":66,"share":26},"Bispecific antibodies",87,{"name":68,"count":17,"share":52},"Non-antibody therapeutic proteins",{"name":70,"count":71,"share":33},"Oligonucleotide and RNA therapeutics",37,{"name":73,"count":71,"share":33},"Vaccines",{"name":75,"count":76,"share":33},"Gene therapies",36,[78,82,85,89,93,95,98,101,104,107],{"name":79,"count":80,"share":81},"melanoma",124,19,{"name":83,"count":84,"share":26},"colorectal cancer (CRC)",81,{"name":86,"count":87,"share":88},"non-small cell lung cancer (NSCLC)",70,11,{"name":90,"count":91,"share":92},"breast cancer",49,8,{"name":94,"count":71,"share":33},"ovarian cancer",{"name":96,"count":97,"share":37},"triple-negative breast cancer (TNBC)",29,{"name":99,"count":100,"share":37},"glioblastoma (GBM)",26,{"name":102,"count":103,"share":37},"pancreatic cancer (PC)",25,{"name":105,"count":106,"share":37},"pancreatic adenocarcinoma (PDAC)",24,{"name":108,"count":60,"share":37},"head and neck squamous cell carcinoma (HNSCC)",[110,112,116,118,120,122,124,127,129,131],{"name":111,"count":32,"share":33},"Bristol Myers Squibb",{"name":113,"count":114,"share":115},"Merck",33,5,{"name":117,"count":45,"share":20},"AstraZeneca",{"name":119,"count":45,"share":20},"Genentech",{"name":121,"count":52,"share":20},"Amgen",{"name":123,"count":52,"share":20},"Novartis",{"name":125,"count":126,"share":20},"Iovance Biotherapeutics",10,{"name":128,"count":126,"share":20},"Pfizer",{"name":130,"count":92,"share":4},"Eli Lilly",{"name":132,"count":21,"share":4},"Johnson & Johnson",[134,144,152,158,167,174,181,189,196],{"title":135,"drug":136,"company":140,"phase":141,"disease":86,"finding":142,"url":143},"539 A randomized, double-blind, phase III trial to compare SB27 (a proposed biosimilar to pembrolizumab) to reference pembrolizumab in participants with metastatic non-squamous non-small cell lung cancer",{"name":137,"slug":138,"named_as":139},"QL2107","ql2107","sb27",null,"Phase 3","ORR at Week 24 was 34.6% in SB27 and 37.9% in Pembro; the ORR ratio was 0.89 and its 90% CI was (0.737, 1.071), which was within the pre-defined margin (FAS).","https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjitc-2026-sitc2026.0539",{"title":145,"drug":146,"company":140,"phase":149,"disease":86,"finding":150,"url":151},"496 Nogapendekin alfa inbakicept (NAI), an IL-15R agonist, prolongs OS in solid tumors after standard-of-care and checkpoint inhibitor (CPI) failure: updated results from QUILT-3.055",{"name":147,"slug":148},"nogapendekin alfa inbakicept","nogapendekin-alfa-inbakicept","Phase 2","Across all tumor types, mOS was 14.3 (95% CI: 12.2-16.9) and 15.8 versus 11.8 months in ALC responders (mean ALC ≥1,000 cells\u002FµL) versus non-responders (hazard ratio [HR] 0.59; P = 0.0281).","https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjitc-2026-sitc2026.0496",{"title":153,"drug":154,"company":125,"phase":149,"disease":79,"finding":156,"url":157},"335 Long-term durable efficacy of lifileucel one-time treatment: post-hoc landmark analysis of overall survival by response in advanced melanoma patients (C-144-01 study)",{"name":155,"slug":155},"lifileucel","Notably, 21 of 28 (75%) 5-year completers (7 CR, 11 PR, 3 SD) remained alive and treatment-free (no new anticancer therapy) with OS of 55.0 to 61.7 months after a single lifileucel infusion.","https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjitc-2026-sitc2026.0335",{"title":159,"drug":160,"company":140,"phase":163,"disease":164,"finding":165,"url":166},"1185 IDP-023 allogeneic g-NK cells combined with isatuximab in relapse\u002Frefractory multiple myeloma: complete safety, efficacy, and tumor microenvironment remodeling from a Phase 1\u002F2 first-in-human study",{"name":161,"slug":162},"IDP-023","idp-023","Phase 1\u002F2","multiple myeloma (MM)","Of 11 efficacy-evaluable IDP-023 + isatuximab patients, overall-response-rate (ORR) was 36% (4\u002F11) and clinical-benefit-rate (CBR) 55% (6\u002F11), versus 0%\u002F3% expected for isatuximab alone in CD38-refractory disease.","https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjitc-2026-sitc2026.1185",{"title":168,"drug":169,"company":140,"phase":163,"disease":83,"finding":172,"url":173},"517 MDNA11 demonstrates clinical activity as monotherapy and in combination with pembrolizumab in biomarker-enriched gastrointestinal malignancies, including ICI-refractory disease",{"name":170,"slug":171},"MDNA11","mdna11","MDNA11 plus pembrolizumab demonstrated an ORR of 57% (4\u002F7; 95% CI: 18–90), including 1 unconfirmed response (lost to follow-up), and a DCR of 86% (6\u002F7; 95% CI: 42–100).","https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjitc-2026-sitc2026.0517",{"title":175,"drug":176,"company":140,"phase":163,"disease":178,"finding":179,"url":180},"611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1\u002F2 study",{"name":177,"slug":177},"imneskibart","cutaneous melanoma (CM)","Imneskibart + IL-2 was well tolerated with Grade 3\u002F4 drug-related adverse events occurring in 14.5 % of pts and in 10.5% of pts who received the combination with nivolumab.","https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjitc-2026-sitc2026.0611",{"title":182,"drug":183,"company":140,"phase":185,"disease":186,"finding":187,"url":188},"1177 Phase 1 evaluation of brenetafusp alone and in combination with tebentafusp in metastatic uveal melanoma",{"name":184,"slug":184},"brenetafusp","Phase 1","intraocular melanoma","Among 1L mUM patients (n = 17), tebentafusp + brenetafusp treatment was associated with favorable efficacy outcomes with 29% ORR, 24.1-month median DOR, 8.1-month median PFS, 88% 1-yr OS, and 70% 2-yr OS.","https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjitc-2026-sitc2026.1177",{"title":190,"drug":191,"company":140,"phase":185,"disease":193,"finding":194,"url":195},"563 Updated safety and efficacy of AN4005, an oral small-molecule PD-L1 inhibitor, in advanced solid tumors: phase I dose-escalation and expansion",{"name":192,"slug":192},"an4005","Nonhematologic neoplasms","Rash was more frequent in Part 3 than in Parts 1–2 (48% vs 2.9%) and had an early onset (median = 10 days), with most events manageable.ss In ASPS (Cohort 3A), ORR was 15% and the DCR was 60%; median duration of response was not reached.","https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjitc-2026-sitc2026.0563",{"title":197,"drug":198,"company":140,"phase":185,"disease":201,"finding":202,"url":203},"534 High immunosuppressive-free response rate of immune checkpoint inhibitor (ICI)-related enterocolitis with SER-155, an investigational oral live biotherapeutic, in a phase 1b study",{"name":199,"slug":200},"SER-155","ser-155","enterocolitis","Two participants (13%) experienced a serious TEAE, neither attributed to SER-155.","https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjitc-2026-sitc2026.0534",{"summary":205,"bullets":207},[206],"Monoclonal antibodies, the most frequent modality, accounted for 28% of drug-linked abstracts, up from 22% in 2025. Small molecules accounted for 23% of drug-linked abstracts, up from 19% in 2025. CD28 (2%) was new to the top targets compared with 2025.",[208,209,210,211,212],"PDCD1 was the most frequent target (13% of drug-linked abstracts).","Melanoma was the most frequent disease (19%).","Bristol Myers Squibb had the largest company share (6%).","CD19 accounted for 4% of drug-linked abstracts, down from 6% in 2025.","CD274 accounted for 6% of drug-linked abstracts, up from 4% in 2025.",[214],{"year":215,"abstracts":216},2025,1283,{"previous_year":215,"abstracts":218,"targets":220,"modalities":227,"new_in_top_targets":237,"new_in_top_modalities":238},{"previous":216,"current":13,"change_pct":52,"direction":219},"fell",[221,223,225],{"name":31,"count":32,"share":33,"previous_count":106,"previous_share":37,"direction":222},"rose",{"name":24,"count":25,"share":26,"previous_count":224,"previous_share":88,"direction":222},64,{"name":35,"count":36,"share":37,"previous_count":226,"previous_share":33,"direction":219},34,[228,231,233,235],{"name":55,"count":56,"share":36,"previous_count":229,"previous_share":230,"direction":222},133,22,{"name":58,"count":59,"share":60,"previous_count":232,"previous_share":81,"direction":222},110,{"name":68,"count":17,"share":52,"previous_count":234,"previous_share":126,"direction":222},59,{"name":73,"count":71,"share":33,"previous_count":236,"previous_share":92,"direction":219},50,[51],[],[240,244],{"name":241,"count":242,"share":115,"previous_count":100,"previous_share":37,"direction":243},"Antibody-drug conjugates",35,"flat",{"name":65,"count":66,"share":26,"previous_count":245,"previous_share":52,"direction":243},71,1794807930042]